Welcome to our dedicated page for Springworks Therapeutics SEC filings (Ticker: SWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial footnotes, R&D cost drivers, milestone payments, and FDA status hide deep in SpringWorks Therapeutics� multi-section 10-K. For analysts chasing desmoid-tumor data or confirming cash runway before the next pivotal read-out, scrolling hundreds of biotech pages wastes hours. The challenge intensifies when insider activity posts on Form 4 minutes after market close. Investors need answers fast, not another PDF.
Stock Titan surfaces what matters the instant an SWTX document hits EDGAR. Our AI-powered summaries translate scientific jargon and accounting detail into plain English, delivering real-time filing updates as they’re published to EDGAR. Whether you’re reviewing a SpringWorks Therapeutics quarterly earnings report 10-Q filing, scanning an unexpected 8-K material event, or comparing figures in the latest SpringWorks Therapeutics proxy statement executive compensation disclosure, our platform highlights pipeline updates, royalty obligations, and cash burn without line-by-line reading.
Every filing type is covered:
- SpringWorks Therapeutics insider trading Form 4 transactions with alert history
- SpringWorks Therapeutics quarterly earnings report 10-Q filing trend charts
- SpringWorks Therapeutics executive stock transactions Form 4 in real time
- SpringWorks Therapeutics annual report 10-K simplified for quick reference
- SpringWorks Therapeutics 8-K material events explained
- Understanding SpringWorks Therapeutics SEC documents with AI
Stop guessing when executives sell shares or when milestone payments hit the balance sheet. With expert annotations, keyword search across all SpringWorks Therapeutics filings, and side-by-side PDF comparison, you get SpringWorks Therapeutics earnings report filing analysis in seconds—clarity and speed every time the company presses “submit.�
SpringWorks Therapeutics, Inc. (SWTX) has filed a Form 25 with the U.S. Securities and Exchange Commission. Nasdaq Stock Market LLC, acting as the filer, is removing the company’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The form certifies that Nasdaq has complied with the procedural requirements of 17 CFR 240.12d2-2(b), which allows an exchange to strike a security from listing, and notes that the issuer has likewise satisfied the conditions for voluntary withdrawal under 17 CFR 240.12d2-2(c) if applicable.
The document contains no explanation for the delisting, nor does it provide financial statements or indicate any concurrent corporate action such as a merger, acquisition, or transfer to another trading venue. The filing was signed on 1 July 2025 by Tara Petta, AVP, on behalf of Nasdaq Stock Market LLC. Once effective—generally 10 days after filing—the company’s common stock will no longer be traded on Nasdaq, and its Section 12(b) registration will be withdrawn.
SpringWorks Therapeutics (Nasdaq:SWTX) filed an 8-K reporting the June 26, 2025 special meeting results regarding its proposed acquisition by Merck KGaA, Darmstadt, Germany.
- Quorum: 59.0 million shares (78.31% of outstanding) were represented.
- Merger Agreement adopted with 58.90 million FOR, 0.09 million AGAINST, 0.01 million ABSTAIN (99.85% support).
- Because Proposal 1 passed decisively, the Adjournment Proposal was not needed.
- Advisory compensation for named executives linked to the merger also passed (92% support).
The shareholder vote removes a key closing condition; the transaction now awaits customary regulatory and other approvals. The filing reiterates forward-looking-statement caveats and outlines risks such as termination rights, regulatory delays and litigation.
FAQ
What is the current stock price of Springworks Therapeutics (SWTX)?
What is the market cap of Springworks Therapeutics (SWTX)?
